66 results on '"Low, Eric"'
Search Results
2. OP87 A Roadmap for Increasing The Usefulness And Impact Of Patient Preference Studies In Health Technology Assessment (HTA)
3. Esophageal anatomy and physiology vary across spastic and non‐spastic phenotypes of disorders of esophagogastric junction outflow
4. Risk of Esophageal Cancer in Achalasia: A Matched Cohort Study Using the Nationwide Veterans Affairs Achalasia Cohort
5. Development and Validation of the Veterans Affairs Eosinophilic Esophagitis Cohort
6. S540 Helicobacter pylori Is Associated With a Significantly Reduced Risk of Eosinophilic Esophagitis: A Cohort Study Using the National Veterans Health Administration Data
7. Utility of Functional Lumen Imaging Probe in the Evaluation of Esophageal Conditions
8. Commentary: Advocating for patient and public involvement and engagement in health economic evaluation
9. Estimated Burden of Screening for Barrett’s Esophagus in the United States
10. Evaluation of Esophageal Dysphagia in Elderly Patients
11. Management of Non-achalasia Esophageal Hypercontractility: EGJ Outflow Obstruction and Hypercontractile Esophagus
12. Identifying spastic variant of type II achalasia after treatment with high‐resolution manometry and FLIP Panometry
13. Comprehensive Review of Cratoxylum Genus: Ethnomedical Uses, Phytochemistry, and Pharmacological Properties
14. A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force
15. Chagas' disease achalasia may represent a sub‐group of type 2 achalasia without focal elevated pressures
16. OP84 Cost Consequence Analysis: A Potential Framework To Incorporate Patient Preferences Into Health Technology Assessment And Reimbursement Decisions
17. Narrowing the Quality Chasm in Achalasia
18. S388 Risk of Esophageal Cancer in Achalasia: A Matched Cohort Study Utilizing the Veterans Affairs Achalasia Cohort (VA-AC)
19. Development and Validation of a National US Achalasia Cohort: The Veterans Affairs Achalasia Cohort (VA-AC)
20. Type II achalasia with focal elevated pressures: A distinct manometric and clinical sub‐group
21. Editorial: reducing false alarms with oesophagogastric junction outflow obstruction
22. Evolution and evidence-based adaptations in techniques for peroral endoscopic myotomy for achalasia
23. Sa1200: RISK FOR ESOPHAGEAL CANCER AMONG INDIVIDUALS WITH ACHALASIA: A NATIONAL COHORT STUDY
24. Su1078: DEVELOPMENT AND VALIDATION OF A UNITED STATES NATIONAL ACHALASIA COHORT
25. Draft Genome Sequence of the Marine Bioluminescent Bacterium Aliivibrio fischeri ATCC 7744
26. Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study
27. S454 Utility of High Resolution Manometry, Barium Esophagram and Endoscopic Ultrasound to Assess Length of Spastic Segment in Type 3 Achalasia
28. S483 Esophageal Circular Muscle Thickness With Endoscopic Ultrasound Among Esophageal Motility Disorders
29. Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial
30. Letter of support from Eric Low, Director, Eric Low Consulting, Edinburgh, UK
31. A multidisciplinary personalised paradigm for achalasia
32. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
33. Risk Factors for Early-Onset Colorectal Cancer
34. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
35. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
36. 982 – Risk Factors for Early-Onset Colorectal Cancer in a Sample of 68,067 US Veterans Undergoing Colonoscopy 1999-2014
37. Levofloxacin Prophylaxis in Newly Diagnosed Myeloma Patients
38. Incidence and Characterization of Major Upper-Extremity Amputations in the National Trauma Data Bank
39. Financing From the Perspective of Mining Companies
40. Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
41. Patient Perception of Being Involved in a Clinical Trial for Multiple Myeloma Ceri Bygrave, Tanya Burton*, Patricia Carter, Sarah Richard, Eric Low, Charlotte Bloodworth
42. Complications and revision amputation following trauma-related lower limb loss
43. WHY PATIENTS SHOULD BE INVOLVED IN HEALTH TECHNOLOGY ASSESSMENT
44. A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial
45. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial
46. Accelerating target discovery using pre-competitive open science— patients need faster innovation more than anyone else
47. Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
48. The Surgical Clerkship and Medical Student Performance in a Standardized Patient Case of Acute Cholecystitis
49. Time to redefine Myeloma
50. Enrichment of human embryonic stem cell derived motor neuron cultures using arabinofuranosyl cytidine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.